Cargando…
Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab
BACKGROUND: Branch retinal vein occlusion is a frequent cause of visual loss with currently insufficient treatment options. We evaluate the effect of Bevacizumab (Avastin(®)) treatment in patients with macular edema induced by branch retinal vein occlusion. METHODS: Retrospective analysis of 32 eyes...
Autores principales: | Abegg, Mathias, Tappeiner, Christoph, Wolf-Schnurrbusch, Ute, Barthelmes, Daniel, Wolf, Sebastian, Fleischhauer, Johannes |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566976/ https://www.ncbi.nlm.nih.gov/pubmed/18823536 http://dx.doi.org/10.1186/1471-2415-8-18 |
Ejemplares similares
-
Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017) -
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir, Mehmet, et al.
Publicado: (2011) -
Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
por: Thapa, Raba, et al.
Publicado: (2012) -
Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Kim, Jin Young, et al.
Publicado: (2009) -
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce, Gokcen, et al.
Publicado: (2014)